Moleculin Biotech (MBRX) CEO Walter Klemp Sells 360 Shares

Walter Klemp, CEO and President of MBRX, sold 360 shares of the company on June 22, 2026. The transaction didn't disclose a value. This move comes as part of a series of insider trading activities within the company.

Insider Buying and Selling at Moleculin Biotech, Inc.

On June 22, 2026, several insiders engaged in trading activities at MBRX. Walter Klemp, the CEO and President, sold 360 shares without a disclosed price or value. Additionally, Jonathan Foster, the Chief Financial Officer, sold 41 shares at $3.12 each and purchased 174 shares. Donald Picker, the Chief Science Officer, also traded shares, buying 71 shares and selling 21 shares at $3.12 each.

Other Institutional Activity in MBRX

Several institutional investors have shown interest in MBRX. Sabby Management, LLC opened a new position with 75,021 shares valued at about $171,798. Geode Capital Management, LLC increased its holdings by 17,191 shares, resulting in 32,329 shares worth approximately $74,033, marking a 113.6% increase. Rockefeller Capital Management L.P. significantly boosted its stake by 4,203 shares, reaching 4,421 shares valued at $10,124, a 1,928% increase.

Moleculin Biotech, Inc. Stock Up 279.0%

Shares of MBRX traded around $2.93 on Thursday. The stock has seen various institutional activities and insider transactions recently. However, specific metrics like market cap, P/E ratio, or beta were not available at this time.

Analysts Set New Price Targets

On March 24, 2026, HC Wainwright & Co. reiterated its buy rating for MBRX with a price target of $22. Previously, on December 11, 2025, the firm maintained its buy rating with the same target. The consensus among analysts remains positive, with multiple firms holding a buy rating on the stock.

Bottom Line

Walter Klemp's sale of shares is part of broader insider trading activity at MBRX. Investors often watch such moves to gauge insider sentiment, but these transactions do not necessarily indicate the company's future performance. Institutional interest and analyst ratings suggest continued attention on MBRX, though it's important to remember that insider trades are disclosed after the fact and may not reflect current positions.